Alzheimer's Disease Risk Genes Identified in Landmark Study

Alzheimer’s disease is the leading cause of dementia worldwide and poses a significant public health challenge1 . Recent large-scale genetic studies have dramatically expanded our understanding of the genes involved in Alzheimer’s, revealing many new risk loci that contribute to the disease2 . These discoveries provide a more detailed picture of the genetic factors influencing Alzheimer’s and open new avenues for research into prevention and treatment3 .

💡 Did You Know? A major international study involving UK Dementia Research Institute researchers identified 75 genes linked to Alzheimer’s risk, marking a landmark achievement in the field3 .

Study Scope and Key Findings

The largest genome-wide association study (GWAS) conducted to date analyzed genetic data from over 1.1 million individuals, including more than 111,000 people clinically diagnosed with Alzheimer’s disease and over 677,000 cognitively healthy controls2 4. This unprecedented scale enabled the identification of 75 gene loci associated with increased Alzheimer’s risk, of which 42 were novel discoveries5 24. These findings confirm that Alzheimer’s disease is highly heritable, with genetics accounting for approximately 60% to 80% of an individual’s risk5 3.

The newly identified genes implicate diverse biological pathways beyond the well-known amyloid beta and tau protein abnormalities traditionally linked to Alzheimer’s. Notably, many of these genes are involved in immune system regulation and inflammation, highlighting the role of neuroinflammation in disease progression6 . For example, several genes affect microglia, the brain’s immune cells responsible for clearing damaged neurons and cellular debris. Dysfunction in microglial activity may accelerate Alzheimer’s pathology by impairing this “taking out the trash” function6 .

Additional pathways uncovered include those related to tumor necrosis factor alpha (TNF), a key inflammatory regulator, and lipid metabolism, which is critical for maintaining healthy cell membranes and neuronal function7 6. The study also suggests a genetic overlap between Alzheimer’s and other neurodegenerative diseases such as Parkinson’s disease and Lewy body dementia, indicating a potential continuum of neurodegenerative processes6 .

Precision Medicine in Alzheimer’s: The expanding list of Alzheimer’s risk genes is transforming research toward precision medicine. By understanding individual genetic profiles, scientists aim to develop tailored treatments that address specific disease mechanisms, improving outcomes for patients. 269

A genetic risk score (GRS) was developed based on these gene variants to estimate an individual’s likelihood of developing Alzheimer’s disease. While promising for research and clinical trial applications, this score is not yet ready for routine clinical use2 8. The GRS may help identify individuals at high risk and improve drug evaluation by stratifying participants in clinical studies8 .

Key insights from the study include:

• Identification of 75 Alzheimer’s disease risk loci, including 42 novel genes5 24.
• Confirmation that genetics contribute to 60–80% of Alzheimer’s risk5 3.
• New genes implicate immune regulation, inflammation, and microglial dysfunction6 .
• Evidence of shared genetic factors across multiple neurodegenerative diseases6 .
• Development of a genetic risk score to predict Alzheimer’s susceptibility2 8.

“Some of the newly discovered genes may cause microglia to be less efficient, which could accelerate the disease.”

— Expert commentary on microglial role in Alzheimer’s6

• Immune system regulation and microglial function
• Inflammatory pathways involving tumor necrosis factor alpha (TNF)
• Lipid metabolism and cell membrane maintenance
• Protein processing and clearance mechanisms
• Overlapping genetic factors with Parkinson’s and Lewy body dementia

Implications for Alzheimer's Disease Treatment

The discovery of 42 new Alzheimer’s risk genes represents a significant step forward in understanding the disease’s complex genetic architecture2 9. These findings pave the way for the development of gene-specific therapies and personalized medicine approaches tailored to an individual’s genetic profile9 . However, further research is essential to elucidate the precise biological roles of these genes and how they contribute to disease onset and progression9 .

Genetic risk scores derived from these studies offer valuable tools for predicting Alzheimer’s risk and could facilitate earlier diagnosis and intervention strategies in the future8 . Although not yet approved for clinical use, these scores may enhance clinical trial design by identifying high-risk participants and improving drug efficacy assessments2 8.

“From APOE4 to ABCA7 loss of function, disruption of lipid homeostasis leads to Alzheimer’s pathology, and restoring lipid balance through choline supplementation can ameliorate these effects.”

— Djuna von Maydell, MIT7

Recent research on rare gene variants, such as those in the ABCA7 gene, has revealed mechanisms by which lipid metabolism disruption contributes to Alzheimer’s pathology. Dysfunctional ABCA7 variants impair lipid transport across neuronal membranes, leading to mitochondrial stress, oxidative damage, and increased amyloid beta accumulation7 . Encouragingly, treatment with choline precursors like CDP-choline has been shown to reverse these cellular defects in laboratory models, suggesting potential therapeutic avenues7 .

Similarly, gene variants affecting the blood-brain barrier, such as a protective fibronectin mutation, may influence amyloid clearance and offer targets for novel drug development10 . This variant reduces excess fibronectin accumulation, which otherwise impedes amyloid removal from the brain, highlighting the importance of vascular contributions to Alzheimer’s disease10 .

NIH-supported research is actively exploring gene therapies aimed at modifying the expression of risk genes like APOE ε4 and protective genes such as APOE ε2. These approaches seek to reduce amyloid deposition, neuroinflammation, and neurodegeneration, with several candidates advancing through clinical trials11 . Additionally, novel drugs targeting amyloid production and other pathological proteins are under investigation, including compounds designed specifically for individuals with high-risk genotypes like APOE4 homozygotes11 12.

💡 Did You Know? NIH supports over 25 new Alzheimer’s drug candidates in human trials, including gene therapies and immunotherapies targeting genetic risk factors11 .

Lifestyle interventions remain a critical component of risk reduction, especially for individuals with high genetic susceptibility. Studies emphasize the benefits of Mediterranean diet, physical exercise, cognitive training, and stress management in delaying symptom onset and preserving cognitive function12 .

Therapeutic implications include:

• Potential for gene-specific and personalized treatments based on newly identified risk genes2 9.
• Use of genetic risk scores to improve early diagnosis and clinical trial stratification2 8.
• Targeting lipid metabolism dysfunction, e.g., ABCA7 variants, with choline supplementation7 .
• Development of drugs modulating blood-brain barrier proteins like fibronectin to enhance amyloid clearance10 .
• Ongoing gene therapy trials aiming to modify APOE gene expression and reduce neurodegeneration11 .
• Experimental drugs designed for APOE4 homozygotes to prevent amyloid plaque formation without adverse effects12 .
• Continued emphasis on lifestyle modifications to mitigate genetic risk12 .

“People want to know their chances of developing Alzheimer’s and what they can do about it. In the near future, genetic risk scores will help guide precision medical and lifestyle management.”

— Dr. Richard Isaacson, Alzheimer’s Prevention Clinic6